Perspective on the optimal endpoints for pulmonary arterial hypertension trials

Current Opinion in Pulmonary Medicine

Volumn 16, Issue SUPPL. 1, 2010, Pages

  Rubin, Lewis ^a   Simonneau, Gérald ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

Clinical worsening; Mortality; Time to clinical worsening

Indexed keywords

OXYGEN; PROSTACYCLIN;

BLALOCK HANLON OPERATION; CLINICAL TRIAL; DISEASE COURSE; HUMAN; PULMONARY HYPERTENSION; REVIEW; TRANSPLANTATION;

DISEASE PROGRESSION; ENDPOINT DETERMINATION; EXERCISE TOLERANCE; HUMANS; HYPERTENSION, PULMONARY; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77951045619     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/01.mcp.0000370210.53379.b3     Document Type: Review

References (19)

1. Galiè N, Simonneau G, Barst RJ, et al. Endpoints in trials of pulmonary arterial hypertension: importance of time to clinical worsening. Curr Opin Pulm Med (in press).
2. Peacock A, Keogh A, Humbert M. Clinical worsening in trials of pulmonary arterial hypertension: results and implications. Curr Opin Pulm Med (in press).
3. Haworth SG and Beghetti M. Assessment of endpoints in the pediatric population: congenital heart disease and idiopathic pulmonary arterial hypertension. Curr Opin Pulm Med (in press).
4. Coghlan JG, Pope J, Denton CP. Assessment of endpoints in pulmonary arterial hypertension associated with connective tissue disease. Curr Opin Pulm Med (in press).
5. Macchia A, Marchioli R, Marfisi R, et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 2007; 153:1037-1047.
6. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelinreceptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358:1119-1123. (Pubitemid 32971843)
7. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896-903.
8. Galiè N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double- blind, randomised controlled trial. Lancet 2008; 371:2093-2100.
9. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169:441-447.
10. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47:2049-2056.
11. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117:3010-3019.
12. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353:2148-2157. (Pubitemid 41653106)
13. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119:2894-2903.
14. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174:1257-1263.
15. Simonneau G, Rubin LJ, Galiè N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008; 149:521-530.
16. Hoeper MM, Markevych I, Spiekerkoetter E, et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005; 26:858-863.
17. Sitbon O, Hoeper MM, Simonneau G. Assessing effectiveness of pulmonary arterial hypertension therapies in daily practice. Curr Opin Pulm Med (in press).
18. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30:2493-2537.
19. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54 (1 Suppl):S78-S84.